RxDoctor Payments Data

Keith Preis, MD

Neurology · Cherry Hill, NJNPI 1750317301

Payments from drug & device makers

$36,383in general payments, 2019–2025

Across 2,096 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$7K
  • AbbVie$5K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Bristol Myers Squibb$2K
  • UCB, Inc.$2K
  • Biogen$2K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$270%
  • Food & beverage$35,55198%
  • Education$8062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.325$6,741
AbbVie(2 entities)298$4,515
E.r. Squibb & Sons, L.L.C.44$2,438
Bristol Myers Squibb131$2,342
UCB, Inc.109$1,901
Biogen110$1,763
Teva Pharmaceuticals USA, Inc.127$1,640
Axsome Therapeutics, Inc.58$1,052
Pfizer85$858
Novartis57$717
Amgen(2 entities)34$690
ANI Pharmaceuticals, Inc.40$664
Jazz Pharmaceuticals Inc.32$594
Lilly USA, LLC49$584
Avanir Pharmaceuticals, Inc.31$517
AstraZeneca(2 entities)26$487
Neurocrine Biosciences, Inc.29$438
Genentech USA, Inc.19$419
Sanofi21$404
Lundbeck LLC23$403
Eisai Inc.24$372
Amneal Pharmaceuticals LLC25$371
Biohaven Pharmaceutical Holding Company Ltd.32$368
Scilex Pharmaceuticals Inc.27$357
Johnson & Johnson(2 entities)18$331
Mallinckrodt Hospital Products Inc.18$324
Impel Pharmaceuticals Inc.9$320
Merz Pharmaceuticals, LLC10$314
Acadia Pharmaceuticals Inc24$265
Upsher-smith Laboratories LLC15$222
Kyowa Kirin, Inc.14$215
SK Life Science, Inc.7$215
Supernus Pharmaceuticals, Inc.15$194
MDD US Operations, LLC10$188
Argenx US, Inc.11$181
Boston Scientific8$179
Otsuka America Pharmaceutical, Inc.4$177
Vanda Pharmaceuticals Inc.11$169
Takeda Pharmaceuticals U.S.A., Inc.11$168
Biohaven Pharmaceuticals, Inc.15$157
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$150
Neurelis, Inc.11$149
Arbor Pharmaceuticals, Inc.10$149
Harmony Biosciences LLC10$146
Sunovion Pharmaceuticals Inc.12$118
Averitas Pharma Inc.6$118
Almatica Pharma LLC6$89
Avadel CNS Pharmaceuticals, LLC5$78
Impel Pharmaceuticals LLC4$73
Adlon Therapeutics L.p.5$71
GRT US Holding, Inc.7$70
TG Therapeutics, Inc.4$69
Assertio Therapeutics, Inc.5$69
W. L. Gore & Associates, Inc.4$68
Currax Pharmaceuticals LLC4$60
Mallinckrodt Enterprises LLC4$58
Acorda Therapeutics, Inc4$57
Merz North America, Inc.2$52
Ipsen Biopharmaceuticals, Inc3$47
Azurity Pharmaceuticals, Inc.3$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,383 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$85,275
Medicare patients
252
Services billed
743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate13$120,845
IngrezzaValbenazine Tosylate12$103,711
VumerityDiroximel Fumarate12$99,829
ZeposiaOzanimod Hydrochloride11$95,872
Nurtec OdtRimegepant Sulfate27$32,614
BotoxOnabotulinumtoxina25$30,811
Glatiramer Acetate18$30,069
HorizantGabapentin Enacarbil34$26,663
QuliptaAtogepant15$23,345
Aimovig AutoinjectorErenumab-Aooe15$20,911
NeuproRotigotine21$17,576
UbrelvyUbrogepant12$17,201
Memantine Hcl ErMemantine Hcl101$8,492
Modafinil39$7,346
Pregabalin147$3,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$1,763$220,67425 claims
Neurocrine Biosciences, Inc.Ingrezza$438$103,71112 claims
E.r. Squibb & Sons, L.L.C.Zeposia$2,438$95,87211 claims
AbbVieBotox, Qulipta, Ubrelvy$4,515$71,35652 claims
PfizerNurtec Odt$858$32,61427 claims
Arbor Pharmaceuticals, Inc.Horizant$149$26,66334 claims
UCB, Inc.Neupro$1,901$17,57621 claims
Upsher-smith Laboratories LLCTopiramate$222$1,001105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →